Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority to DO2003000674ApriorityCriticalpatent/DOP2003000674A/en
Publication of DOP2003000674ApublicationCriticalpatent/DOP2003000674A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La administración de un inhibidor irreversible de tirosina quinasa tal como C1-1033 en combinación con uno o más agentes antineoplasicos, o radiación ionizante, es sinérgica para tratar el cancer.The administration of an irreversible tyrosine kinase inhibitor such as C1-1033 in combination with one or more antineoplastic agents, or ionizing radiation, is synergistic to treat cancer.
DO2003000674A2003-07-232003-07-23
THERAPEUTIC COMBINATIONS OF ERB B QUINASA INHIBITORS AND ANTINEOOLASIC THERAPIES
DOP2003000674A
(en)
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
Compounds derived from pyrimidine, tyrosine kinase inhibitors; pharmaceutical compositions comprising them; and its use in the treatment and / or prevention of cancer, inflammatory diseases and autoimmune diseases.
USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER